February 22, 2026 a 12:38 pm
SYK: Analysts Ratings - Stryker Corporation
Stryker Corporation, operating in the medical technology field, shows robust analyst ratings with sustained investment confidence. The company's diversified segments allow it to navigate industry challenges effectively. A breakdown of recent analyst activity reveals the resilience and strengths in its market position.
Historical Stock Grades
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 9 | |
| Buy | 12 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, analyst sentiment for Stryker has remained largely stable, with minor fluctuations in the strong buy and buy categories. The total number of recommendations shows a solid interest in the stock, reflecting an ongoing confidence in its market potential.
- The number of "Strong Buy" recommendations has seen slight increases from 7 to 9.
- Buy ratings have varied slightly, with a drop from a peak of 14 in previous months to 12.
- Hold opinions have remained relatively constant with only slight changes.
Percentage Trends
The distribution of recommendations indicates a strong leaning toward positive sentiment, though a cautious approach is still visible. The subtle shift from strong buy to hold indicates an emphasis on cautious optimism without a drastic move into sell territory.
- August 2025 saw the highest number of buy ratings at 60% of total ratings.
- Recent months report 45% strong buy and 40% hold, indicating a balanced sentiment.
- Market trends suggest a consistent belief in the stock's stability.
Latest Analyst Recommendations
The most recent analyst activity reflects a consistent support for the stock, with most analysts maintaining their previous ratings. There has been a notable diversity of opinions, but the overriding sentiment remains positive.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-30 | Buy | Buy | BTIG |
| 2026-01-30 | Buy | Buy | Needham |
| 2026-01-09 | Outperform | Outperform | Bernstein |
| 2025-12-19 | Market Outperform | Market Perform | Citizens |
| 2025-12-18 | Hold | Hold | Truist Securities |
Analyst Recommendations with Change of Opinion
Recommendations with upgraded opinions indicate a strong shift towards confidence in the stock's future performance. The last few years showed decisive changes in analyst perceptions, adding to the stock's optimistic outlook.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-19 | Market Outperform | Market Perform | Citizens |
| 2024-12-02 | Overweight | Equal Weight | Morgan Stanley |
| 2024-05-22 | Buy | Hold | Needham |
| 2024-01-31 | Buy | Hold | Canaccord Genuity |
| 2023-09-05 | Buy | Neutral | B of A Securities |
Interpretation
The persistent positive sentiment from analysts indicates a strong belief in Stryker's competitive positioning within the medical technology industry. The consistent upgrades and stable buy and outperform recommendations point to increased confidence. While some downgrades exist, these appear to be minor amidst the broader optimistic outlook.
Conclusion
Stryker Corporation continues to captivate analyst interest, with strong buy and buy recommendations dominating the sentiment. The consistent performance and robust innovation pipeline of the company bode well for future growth. While competition in the medical technology sphere remains fierce, Stryker's adaptive strategies and diversified product offerings provide solid opportunities. Overall, the stock seems to exhibit stability, with less volatility expected in upcoming quarters.